News & Updates

The MolGen platform screened over 400 million molecular configurations to surface three previously unknown binding sites in treatment-resistant tumor cell lines — all validated in follow-up biochemical assays within two weeks of computational discovery.

In a 30-day closed-loop experiment, the AutoLab self-driving laboratory platform ran 4,200 experimental cycles without human intervention — delivering a lead compound with 40-fold improved potency over the starting hit, comparable to a six-month human-directed effort.

FoldBase's latest prediction pipeline matched or exceeded X-ray crystallography accuracy across a benchmark set of 140 industrially relevant enzyme classes — at 1,000 times the speed of experimental determination.

A 120-patient clinical pilot at three research hospital partners demonstrated that RareDx's AI diagnostic engine reduced median time to correct genetic diagnosis from 5.2 years to under 11 months — with a 94% concordance rate with specialist review.

A collaboration with three clinical research centers demonstrated the ability to identify polygenic risk scores for rare diseases at population scale — a task that would have required weeks of bioinformatics work three years ago.

Six FDA-approved compounds flagged by the RepurposeAI knowledge graph platform were confirmed active in cell-based assays against three neglected tropical disease pathogens, with two advanced to in vivo efficacy studies.

Real-time AI bioreactor control demonstrated a 23% improvement in monoclonal antibody yield compared to standard batch control parameters — with simultaneous reductions in batch failure rates and process deviations.

The EnzymeAI platform engineered a thermostable variant of a key industrial enzyme with a 40°C improvement in melting temperature and preserved catalytic activity — enabling its use in high-temperature biomanufacturing processes.

A prospective 1,240-patient multicenter study showed AI-guided tumor genomic analysis reduced time to matched therapy selection from 21 days to 5.7 days, with 89% concordance with multidisciplinary tumor board consensus.